163 related articles for article (PubMed ID: 34538401)
1. RAMPART: A model for a regulatory-ready academic-led phase III trial in the adjuvant renal cell carcinoma setting.
Meade A; Oza B; Frangou E; Smith B; Bryant H; Kaplan R; Choodari-Oskooei B; Powles T; Stewart GD; Albiges L; Bex A; Choueiri TK; Davis ID; Eisen T; Fielding A; Harrison DJ; McWhirter A; Mulhere S; Nathan P; Rini B; Ritchie A; Scovell S; Shakeshaft C; Stockler MR; Thorogood N; Larkin J; Parmar MKB
Contemp Clin Trials; 2021 Sep; 108():106481. PubMed ID: 34538401
[TBL] [Abstract][Full Text] [Related]
2. RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse.
Oza B; Frangou E; Smith B; Bryant H; Kaplan R; Choodari-Oskooei B; Powles T; Stewart GD; Albiges L; Bex A; Choueiri TK; Davis ID; Eisen T; Fielding A; Harrison D; McWhirter A; Mulhere S; Nathan P; Rini B; Ritchie A; Scovell S; Shakeshaft C; Stockler MR; Thorogood N; Parmar MKB; Larkin J; Meade A
Contemp Clin Trials; 2021 Sep; 108():106482. PubMed ID: 34538402
[TBL] [Abstract][Full Text] [Related]
3. REFINE (REduced Frequency ImmuNE checkpoint inhibition in cancers): A multi-arm phase II basket trial testing reduced intensity immunotherapy across different cancers.
Merrick S; Nankivell M; Quartagno M; Clarke CS; Joharatnam-Hogan N; Waddell T; O'Carrigan B; Seckl M; Ghorani E; Banks E; Edmonds K; Bray G; Woodward R; Bennett R; Badrock J; Hudson W; Langley RE; Vasudev N; Pickering L; Gilbert DC
Contemp Clin Trials; 2023 Jan; 124():107030. PubMed ID: 36519749
[TBL] [Abstract][Full Text] [Related]
4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
5. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
6. Perioperative therapy in renal cancer in the era of immune checkpoint inhibitor therapy.
Kuusk T; Abu-Ghanem Y; Mumtaz F; Powles T; Bex A
Curr Opin Urol; 2021 May; 31(3):262-269. PubMed ID: 33742979
[TBL] [Abstract][Full Text] [Related]
7. Prevalence, Disease-free, and Overall Survival of Contemporary Patients With Renal Cell Carcinoma Eligible for Adjuvant Checkpoint Inhibitor Trials.
Marconi L; Sun M; Beisland C; Klatte T; Ljungberg B; Stewart GD; Dabestani S; Choueiri TK; Bex A
Clin Genitourin Cancer; 2021 Apr; 19(2):e92-e99. PubMed ID: 33526329
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial.
Chamie K; Donin NM; Klöpfer P; Bevan P; Fall B; Wilhelm O; Störkel S; Said J; Gambla M; Hawkins RE; Jankilevich G; Kapoor A; Kopyltsov E; Staehler M; Taari K; Wainstein AJA; Pantuck AJ; Belldegrun AS
JAMA Oncol; 2017 Jul; 3(7):913-920. PubMed ID: 27787547
[TBL] [Abstract][Full Text] [Related]
9. Practice and progress in kidney cancer: methodology for novel drug development.
Rini BI; Weinberg V; Small EJ
J Urol; 2004 Jun; 171(6 Pt 1):2115-21. PubMed ID: 15126769
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial.
Eisen T; Frangou E; Oza B; Ritchie AWS; Smith B; Kaplan R; Davis ID; Stockler MR; Albiges L; Escudier B; Larkin J; Bex A; Joniau S; Hancock B; Hermann GG; Bellmunt J; Hodgkinson E; Stewart GD; Barber J; Brown J; McMenemin R; Nathan P; Pickering LM; Parmar MKB; Meade A
J Clin Oncol; 2020 Dec; 38(34):4064-4075. PubMed ID: 33052759
[TBL] [Abstract][Full Text] [Related]
11. On the development of the Medical Research Council trial of alpha-interferon in metastatic renal carcinoma. Urological Working Party Renal Carcinoma Subgroup.
Fayers PM; Cook PA; Machin D; Donaldson N; Whitehead J; Ritchie A; Oliver RT; Yuen P
Stat Med; 1994 Nov; 13(21):2249-60. PubMed ID: 7846423
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant therapy in renal cell carcinoma-past, present, and future.
Janowitz T; Welsh SJ; Zaki K; Mulders P; Eisen T
Semin Oncol; 2013 Aug; 40(4):482-91. PubMed ID: 23972712
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial.
Motzer RJ; Russo P; Haas N; Doehn C; Donskov F; Gross-Goupil M; Varlamov S; Kopyltsov E; Lee JL; Lim HY; Melichar B; Zemanova M; Rini B; Choueiri TK; Wood L; Reaume MN; Stenzl A; Chowdhury S; McDermott R; Michael A; Izquierdo M; Aimone P; Zhang H; Sternberg CN;
Eur Urol; 2021 Mar; 79(3):334-338. PubMed ID: 33461782
[TBL] [Abstract][Full Text] [Related]
14. Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma.
Karam JA; Devine CE; Urbauer DL; Lozano M; Maity T; Ahrar K; Tamboli P; Tannir NM; Wood CG
Eur Urol; 2014 Nov; 66(5):874-80. PubMed ID: 24560330
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results.
Motzer RJ; Ravaud A; Patard JJ; Pandha HS; George DJ; Patel A; Chang YH; Escudier B; Donskov F; Magheli A; Carteni G; Laguerre B; Tomczak P; Breza J; Gerletti P; Lechuga M; Lin X; Casey M; Serfass L; Pantuck AJ; Staehler M
Eur Urol; 2018 Jan; 73(1):62-68. PubMed ID: 28967554
[TBL] [Abstract][Full Text] [Related]
16. Vaccine therapy in patients with renal cell carcinoma.
Van Poppel H; Joniau S; Van Gool SW
Eur Urol; 2009 Jun; 55(6):1333-42. PubMed ID: 19201522
[TBL] [Abstract][Full Text] [Related]
17. The Midazolam RAMPART Study Medical Records Project: A Unique Use of Real-World Data in a Complex Collaborative Partnership to Support a New Drug Application.
Sherman NA; Silbergleit R; Bengelink EM; Durkalski V; Wolter KD
Ther Innov Regul Sci; 2023 Jan; 57(1):132-141. PubMed ID: 35987977
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant and neoadjuvant therapy for renal cell carcinoma: a survey of the Society of Urologic Oncology.
Tobert CM; Uzzo RG; Wood CG; Lane BR
Urol Oncol; 2013 Oct; 31(7):1316-20. PubMed ID: 22264501
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
Zhao J; Zhu Y; Zhang C; Wang X; He H; Wang H; Wu Y; Zhou W; Shen Z
Urol Oncol; 2013 Nov; 31(8):1800-5. PubMed ID: 22658883
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant and adjuvant strategies in renal cell carcinoma: more questions than answers.
Homicsko K; Berthold DR
Anticancer Drugs; 2011 Jan; 22 Suppl 1():S4-8. PubMed ID: 21173604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]